• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

New not-for-profit drug research organization born

Geneva, Switzerland — 3 Jul 2003
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

A new not-for-profit drug research organization that will harness cutting-edge science to develop medicines for diseases afflicting the world’s poorest people was established today in Geneva. Prestigious health and research institutes from Brazil, France, India, Kenya and Malaysia joined Médecins Sans Frontières to launch the Drugs for Neglected Diseases initiative (DNDi). DNDi will work in close collaboration with the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR) to achieve its goals.

A mere 10% of the world’s health research efforts go into diseases that account for 90% of the global disease burden. “Patients in developing countries are being forced to use drugs with failing efficacy and significant side-effects,” said Dr Yves Champey, interim director of DNDi. “They deserve a better deal. DNDi will mobilize scientific innovation to create new medicines for the world’s most neglected patients.”

At the launch ceremony, the six founding partners gave the commitment of their institutions to do everything possible to support DNDi. The six organisations are the Indian Council of Medical Research, Institut Pasteur (France), the Kenya Medical Research Institute, Médecins Sans Frontières, the Ministry of Health of Malaysia and the Oswaldo Cruz Foundation (Brazil). WHO/TDR will participate in the meetings of the Scientific Advisory Committee of DNDi as an observer to provide expert scientific and technical advice as required.

DNDi plans to spend around US$250 million over 12 years to develop 6-7 drugs and several drugs in the pipeline to combat sleeping sickness, leishmaniasis and Chagas disease – three killer diseases that threaten a combined 350 million people every year. To increase the chance of short and middle-term success, the organisation will develop drugs from existing compounds as well as fund and coordinate research to identify new chemical entities and develop them into drugs.

Over the past months, DNDi has proactively identified a number of promising drug development projects. In addition, with TDR’s help, DNDi also sent a call for letters of interest to the scientific community in February 2003.

“The overwhelming response – 71 project ideas submitted so far – shows that the science for these neglected diseases is out there waiting to be tapped,” said Dr Yves Champey.

“What’s missing is the structure to take the most promising project ideas through the full drug development pipeline. DNDi will provide this structure by capitalizing on existing drug development capacity and expertise in the affected countries.”

DNDi will be the first not-for-profit organisation to exclusively focus on the world’s most neglected diseases. Moving away from the traditional Public Private Partnership structure, it intends to take drug development out of the marketplace by encouraging the public sector to take more responsibility for health. This basic principle is reflected in the composition of its Founding Partners, four of which are public sector institutions.

DNDi’s success will depend not only on government and private donations but also on the contribution of pharmaceutical companies, for instance access to compound libraries, expertise, and research and development facilities.

All the Founding Partners will be in Geneva on 3 and 4 July to attend the launch of DNDi.

Read, watch, share

Loading...
Doctor with patient in hospital setting
Press releases
5 Dec 2023

Cryptococcal meningitis: new report highlights slow uptake of guidelines shown to reduce deaths in Africa

Healthcare worker with patient
Press releases
3 Dec 2023

Germany’s Federal Ministry for Economic Cooperation and Development (BMZ) through KfW grants funding to fast-track access to medicines for poverty-related and neglected diseases

Laboratory staff working
News
3 Dec 2023

DNDi commits to cutting carbon emissions in half by 2030

People entering the Mycetoma Research Centre
Videos
23 Nov 2023

Mycetoma: Neglected but not Forgotten

Nurse caring for patient with a lesion on the feet
Press releases
23 Nov 2023

World’s first clinical trial for devastating fungal disease mycetoma shows efficacy of new, promising treatment

People standing under tents at the Run for Neglected Patients
News
23 Nov 2023

DNDi@20 charity run shines the spotlight on neglected diseases in Kenya

Viewpoints
20 Nov 2023

Africa Statistics Day: Statistics save lives, especially those of neglected patients

Africa Uncensored
Viewpoints
11 Nov 2023

DNDi: 20 years of delivering treatments for neglected patients

MSF Access Campaign Blog
VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License